FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
 - EconoTimes)
NEW ORLEANS, Aug. 18, 2017 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 29, 2017 to file lead plaintiff applications in a securities class action lawsuit against Allergan, Inc. (NYSE:AGN), if they sold call options, purchased put options and/or sold equity forward contracts of the Company between February 25, 2014 and April 21, 2014, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.
What You May Do
If you sold call options, purchased put options and/or sold equity forward contracts of Allergan and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit http://ksfcounsel.com/cases/nyse-agn to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by August 29, 2017.
About the Lawsuit
Allergan and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The Complaint asserts claims under Sections 14(e), 20A and 20(a) of the Securities Exchange Act of 1934 relating to the attempted acquisition of Allergan by Valeant and its affiliates in 2014 in which certain Defendants traded on material non-public information relating to the proposed acquisition, which caused investors to sell call options and equity forward contracts at artificially deflated prices and purchase put options at artificially inflated prices.
About Kahn Swick & Foti, LLC
KSF, whose partners include the former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
